Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Structure Therapeutics Licenses GLP-1 Patents to Roche for $100 Million Upfront

Fineline Cube Jan 8, 2026
Company Deals

Ikarovec and VectorBuilder Sign $1 Billion AAV Capsid Deal for AMD Gene Therapy

Fineline Cube Jan 8, 2026
Company Deals

Mabwell Partners with Sentonix on Neurodegenerative Disease Drug Discovery Alliance

Fineline Cube Jan 8, 2026
Company Deals

Amgen Acquires Dark Blue Therapeutics for $840 Million to Expand AML Portfolio

Fineline Cube Jan 8, 2026
Company Deals

Lilly Nears $1 Billion Deal for Ventyx’s IBD Pipeline

Fineline Cube Jan 7, 2026
Policy / Regulatory

NMPA Releases Draft 102nd Reference Preparations List for Generic Drugs

Fineline Cube Jan 6, 2026
Company Drug

Sichuan Biokin’s BL-B01D1 ADC Wins Priority Review for ESCC in China

Fineline Cube Jan 8, 2026
Company Drug

Zai Lab’s Repotrectinib Wins NMPA sNDA for NTRK Fusion-Positive Solid Tumors

Fineline Cube Jan 8, 2026
Company Deals

Pulnovo Medical Raises ‘Tens of Millions’ in New Financing Round

Fineline Cube Nov 4, 2022

Pulnovo Medical, a pulmonary hypertension (PH) medical device maker based in Wuxi, has reportedly raised...

Company Drug

Akeso Biopharma Completes Enrollment for AK112 Phase III Study

Fineline Cube Nov 4, 2022

China-based Akeso Biopharma (HKG: 9926) has announced the completion of enrollment for its Phase III...

Company Drug

Eccogene Gains FDA Approval for Phase I Study of ECC5004

Fineline Cube Nov 3, 2022

Shanghai-based Eccogene has announced receiving approval from the US FDA to initiate a Phase I...

Company Drug

BeiGene’s Brukinsa Receives EU Marketing Approval for Marginal Zone Lymphoma

Fineline Cube Nov 3, 2022

China-based biotech BeiGene Inc. (NASDAQ: BGNE, HKG: 6160, SHA: 688235) has announced receiving marketing approval from...

Company Deals

Dartsbio Licenses Potential First-in-Class BsAb DS005 to Duality Biologics

Fineline Cube Nov 3, 2022

China-based Dartsbio Pharmaceuticals, Ltd has announced a licensing deal with Duality Biologics, a novel modality...

Company Deals

Fosun Pharma Terminates Equity Transfer Deal with OncoCare Medical

Fineline Cube Nov 3, 2022

Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has announced the termination of...

Company Drug

Antengene’s CD73 Inhibitor ATG-037 Greenlit for Phase I Study by NMPA

Fineline Cube Nov 3, 2022

China-based Antengene Corporation Limited (HKG: 6996) has announced receiving approval from the National Medical Products...

Company Medical Device

Sino Medical Sciences’ Non-Compliant Balloon Catheter Approved by NMPA

Fineline Cube Nov 3, 2022

China-based Sino Medical Sciences Technology Inc. (SHA: 688108) has announced receiving market approval from the...

Company Drug

Hengrui’s Pyrotinib Granted Breakthrough Therapy Designation by CDE

Fineline Cube Nov 3, 2022

The Center for Drug Evaluation (CDE) website indicates that China-based Hengrui Medicine Co., Ltd’s (SHA:...

Company Drug

NMPA Approves Humanwell’s Generic Clobazam for Lennox-Gastaut Syndrome

Fineline Cube Nov 3, 2022

China-based Yichang Humanwell Pharmaceutical Co., Ltd’s generic version (oral suspension) of Sanofi’s clobazam (trade name:...

Company Drug

NMPA Approves Luye Pharma’s LY03005 for Depression Treatment

Fineline Cube Nov 3, 2022

China-based Luye Pharma Group (HKG: 2186) has announced that its Category 1 chemical drug LY03005...

Company Drug Policy / Regulatory

Shanghai SMPA Suspends HEC’s Linagliptin Procurement Over Patent Infringement

Fineline Cube Nov 3, 2022

The Shanghai Sunshine Medical Procurement All-in-One (SMPA) platform has revealed that it has suspended the...

Company Drug

Shanghai Pharmaceuticals Gets NMPA Clearance for Sublingual Rasagiline

Fineline Cube Nov 3, 2022

Shanghai Pharmaceuticals (HKG: 2607, SHA: 601607) has announced receiving clinical clearance from the National Medical...

Company Deals

Baidu Health Partners with Shanghai Epiprobe for Cancer Early Screening

Fineline Cube Nov 3, 2022

China Internet giant Baidu’s Health Internet Hospital unit has announced a partnership with Shanghai Epiprobe...

Company Deals

Pharmaniaga Partners with JD.com to Enter China Market

Fineline Cube Nov 3, 2022

Malaysia-based pharma company Pharmaniaga Berhad (Pharmaniaga) is planning to bring its products into mainland China...

Company Drug

Eli Lilly’s Peresolimab and LOXO-783 Gain Tacit Clinical Trial Approvals in China

Fineline Cube Nov 2, 2022

The Center for Drug Evaluation (CDE) in China has granted tacit clinical trial approvals to...

Company Drug

Hua Medicine Launches Dorzagliatin, a First-in-Class Diabetes Drug, in China

Fineline Cube Nov 2, 2022

China-based Hua Medicine has announced the commercial launch of its Category 1 drug, dorzagliatin, with...

Company Medical Device

Yiming and Hexaell’s HepaCure Biocolumn Receives IND Approval for HBV-Induced Liver Failure

Fineline Cube Nov 2, 2022

China-based Yiming (Beijing) Cell Biotechnology Co., Ltd (also known as Ubrigene) and its partner Shanghai...

Company Drug

Yiming and Vitalgen’s Gene Therapy VGR-R01 Receives CDE Approval for Bietti Crystalline Dystrophy

Fineline Cube Nov 2, 2022

China-based Yiming (Beijing) Cell Biotechnology Co., Ltd (also known as Ubrigene) and its partner Shanghai...

Company Drug

LianBio’s TP-03 Begins Phase III Trial for Demodectic Blepharitis in China

Fineline Cube Nov 2, 2022

Shanghai-based biopharmaceutical company LianBio (OTCMKTS: LIANY) has announced the first patient dosing in a Phase...

Posts pagination

1 … 546 547 548 … 605

Recent updates

  • Structure Therapeutics Licenses GLP-1 Patents to Roche for $100 Million Upfront
  • Sichuan Biokin’s BL-B01D1 ADC Wins Priority Review for ESCC in China
  • Ikarovec and VectorBuilder Sign $1 Billion AAV Capsid Deal for AMD Gene Therapy
  • Zai Lab’s Repotrectinib Wins NMPA sNDA for NTRK Fusion-Positive Solid Tumors
  • Mabwell Partners with Sentonix on Neurodegenerative Disease Drug Discovery Alliance
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Structure Therapeutics Licenses GLP-1 Patents to Roche for $100 Million Upfront

Company Drug

Sichuan Biokin’s BL-B01D1 ADC Wins Priority Review for ESCC in China

Company Deals

Ikarovec and VectorBuilder Sign $1 Billion AAV Capsid Deal for AMD Gene Therapy

Company Drug

Zai Lab’s Repotrectinib Wins NMPA sNDA for NTRK Fusion-Positive Solid Tumors

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.